TARS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tarsus Pharmaceuticals Inc (TARS) is a good buy for a beginner investor with a long-term investment strategy and $50,000-$100,000 available. The company is transitioning into a validated commercial growth story, supported by strong analyst ratings, increasing hedge fund interest, and a positive market outlook for its FDA-approved treatment, XDEMVY. Despite insider selling and short-term technical trends suggesting potential minor declines, the long-term growth potential outweighs these concerns.
The MACD is positively expanding above 0 (0.487), indicating a bullish momentum. RSI is neutral at 65.964, and moving averages are converging, showing no strong directional trend. Key resistance is at 65.285, and support is at 59.185. The stock is trading above its pivot point (61.515), suggesting a positive bias.
Analysts have reiterated strong ratings with price targets of $98-$101, citing Tarsus' successful commercial execution and growth potential.
Hedge funds are significantly increasing their positions, with a 987.14% increase in buying over the last quarter.
The company's Chinese partner received early approval for TP-03, expanding its market reach.
Insiders have significantly increased selling activity by 1503.33% over the last month, which could signal caution.
Short-term stock trend analysis indicates a potential decline of -7.25% in the next month.
No recent news or congress trading data to provide additional confidence.
Financial data is unavailable for the latest quarter. However, analysts project strong growth, with FY2025 net sales of $451.4M and 2026 guidance of $670M-$700M, driven by XDEMVY's market penetration and increasing prescribing depth.
Analysts maintain an Outperform rating with price targets ranging from $98 to $101. They highlight Tarsus' successful transition to a commercial growth story and its strong execution in the U.S. and international markets.
